Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya30914Editorial articleПередовая статьяCardiorenal syndromes: pathogenetic, clinicodiagnostic, prognostic and therapeutic aspectsКардиоренальные синдромы (патогенетические, клинико-диагностические, прогностические и терапевтические аспекты)MoiseevValentin SergeevichМоисеевВалентин Сергеевич

проф., акад. РАМН, зав. каф. факультетской терапии РУДН, руководитель терапевтической клиники ГКБ № 64, тел.: 8-499-134-83-06; Российский университет дружбы народов; городская клиническая больница № 64

KobalavaZhanna DavidovnaКобалаваЖанна Давидовна

проф., зав. каф. пропедевтики внутренних болезней РУДН, ГКБ № 64, тел.: 8-499-134-65-91; Российский университет дружбы народов; городская клиническая больница № 64

MoiseevV S

Russian University of Peoples' Friendship; Moscow City hospital N 64

KobalavaZh D

Russian University of Peoples' Friendship; Moscow City hospital N 64

Российский университет дружбы народовгородская клиническая больница № 64Российский университет дружбы народовRussian University of Peoples' Friendshipгородская клиническая больница № 64Moscow City hospital N 64Russian University of Peoples' FriendshipMoscow City hospital N 64151220118312NO12 (2011)ТОМ 83, №12 (2011)51110042020Copyright ©; 2011, Consilium MedicumCopyright ©; 2011, ООО "Консилиум Медикум"2011Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/30914

Current information on cardiorenal and renocardial relations with clinicopathophysiological disorders in which primary impairment of the heart or kidneys leads to secondary functional and morphological abnormality in the other organ is analysed. Acute decompensation of cardiac failure is wide spread pathology which can be complicated by both acute and chronic lesion of the kidneys. Acute renal failure in cardiogenic shock in patients with ST elevation acute myocardial infarction deteriorates prognosis and raises lethality. Administration of radiopharmaceutical in patients with myocardial infarction and coronary heart disease with stents may induce nephropathy. Synergic affection of the heart and kidneys is observed in diabetes mellitus, systemic lupus erythematosus, amyloidosis, infectious endocarditis and some other diseases.

Обсуждаются современные данные и представления о кардиоренальных и ренокардиальных связях с клинико-патофизиологическими нарушениями, при которых первичное поражение сердца или почек ведет к вторичным функциональным и морфологическим нарушениям в другом органе. Острая декомпенсация сердечной недостаточности является распространенной патологией, которая может осложняться как острым, так и хроническим поражением почек. Острая почечная недостаточность при кардиогенном шоке у больных острым инфарктом миокарда с подъемом сегмента ST ухудшает прогноз и увеличивает летальность. Возможно развитие нефропатии, индуцируемой введением рентгеноконтрастного препарата больным инфарктом миокарда и ИБС с установкой стентов. Синергичное поражение почек и сердца наблюдается при сахарном диабете, системной красной волчанке, амилоидозе, инфекционном эндокардите и некоторых других заболеваниях.

cardiorenal syndromesacute decompensated cardiac failureкардиоренальные синдромыострая декомпенсированная сердечная недостаточностьBerbary A. Links between CKD and cardiovascular disease. In: Berbary A., Mancia G. eds. Cardiorenal syndrome. 2010. 3. a.Моисеев B. C., Мухин H. A., Кобалава Ж. Д. и др. Функциональное состояние почек и прогнозирование сердечно-сосудистого риска. Рекомендации Всероссийского научного общества кардиологов и научного общества нефрологов. Клин. фармакол. и тер. 2009; 4: 1-8.Ronco С. The cardiorenal syndrome: basis and common ground for a multidisciplinary patient-oriented therapy. Cardio Renal Med. 2011; 1 (1): 3-4.Chan E., Dellsperger K. Cardiorenal syndrome: the clinical cardiologists perspective. Cardio Renal Med. 2011; 1 (1): 13-22.Adams K., Fonarow G., Emerman С. et al. ADHERE Investigators: Characteristics and outcomes of patients hospitalized for heart failure in the US. Am. Heart J. 2005; 149: 209.Fonarow G., Adams K., Abraham W. et al. Risk stratification hospital mortality in acutely decompensated heart failure. J. A. M. A., 2005; 293: 572.Koreny M., Karth G., Geppert A. et al. Prognosis of pts who develop acute renal failure during the first 24 hours of cardiogenic shock after MI. Am. J. Med. 2002; 112: 115.Braunwald E., Libby P., Bonow R. et al. Braunwald's heart disease. Philadelphia: Saunders; 2008.Ronco C., House A., Haapio M. Cardiorenal syndrome: refining the definition of a complex symbiosis gone wrong. Intensive Care Med. 2008; 34: 957.Sandler С. Contrast agent induced acute renal dysfunction - is iodixanol the answer? N. Engl. J. Med. 2003; 348: 551.Rudnick M., Goldfarb S., Wexler L. et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 pts. The iohexol study. Kidey Int. 1995; 47: 254.Mehran R., Aymong E., Nikolsky E. et al. A simple risk score for prediction of contrast-induced nephropathy after coronary intervention. J. Am. Coll. Gardiol. 2004; 44: 1393.Nohria A., Hasselblad V., Stebbins A. et al. Cardiorenal interactions: insights from the ESCAPE trial. J. Am. Coll. Gardiol. 2008; 51: 1268.Binanay С., Califf R., Hasselblad V. et al. Evaluation study of heart failure and pulmonary artery catheterisation effectiveness: the ESCAPE study. J. A. M. A. 2005; 294: 1625.Bock J., Gotlieb S. Cardiorenal syndrome: new perspective. Circulation 2010; 121: 2592.Mishra J., Ma Q., Prada A. et al. Identification of lipocalin as a novel urinary biomarker for ischemic renal injury. J. Am. Soc. Nephrol. 2003; 14: 2534.Herget-Rosental S., Marggraf G., Husing J. et al. Early detection of acute renal failure by serum cystatin C. Kidney Int. 2004; 66: 1115.Coresh J., Astor В., Greene T. et al. Prevalence of chronic kidney disease and decreased kidney function in the adult population. Am. J. Kidney Dis. 2003; 41: 1-12.Tonelly M., Wiebe N., Culleton B. et al. Chronic kidney disease and mortality risk. J. Am. Soc. Nephrol. 2006; 17: 2034.Hideki Kawai, Masayoshi Sarai, Hiroto Harigaya. Impact of coronary atherosclerosis in Japanese women with chronic kidney disease. J. Am. Coll. Cardiol. 2011; 57 (14): E354.Baber U., Mehran R., Weisz G. Differences in coronary plaque composition and morphology in patients with and without chronic kidnet disease presenting with acute coronary syndromes: insights from the prospect study. J. Am. Coll. Cardiol. 2011; 57 (15): E1442.Lekawanvijit U., Kompa A., Manabе M., Kelly D. J. Chronic kidney disease-induced cardiac fibrosis is ameliorated by reducing circulating levels of a non-dialysable uremic toxin, indoxyl sylfate. J. Am. Coll. Cardiol. 2011; 57 (17): 914.Ashrith G., Lee V., Elayda M. et al. Outcomes of coronary artery bypass grafting or drug-eluting stent implantation for multyvessel disease in pts with chronic kidney failure. Am. J. Cardiol. 2010; 106: 348.Culleton В., Walsh M., Klarenbach S. et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life. J. A. M. A. 2007; 298: 1291.Morial E. Continuous deteriorated kidney function after coronary intervention is strongly associated with an increased of long term mortality. J. Am. Coll. Cardiol. 2011; 57 (14): E1890.Herzog C., Li S., Weinhandl E. et al. Survival of dialysis pts after cardiac arrest and the impact of cardioverter defibrillators. Kidney Int. 2005; 68: 818.Rubin M., Towensend R. Stroke. ln: Berbary A., Mancia G., eds. Cardiorenal syndrome. J. Am. Coll. Cardiol. Springer; 2010. 205.Bahous S., Delahousse M., Safar M. Aortic stiffness, kidney disease and transplantation. In: Berbary A., Mancia G., eds. Cardiorenal syndrome. Springer; 2010. 255.London G., Pannier В., Marchais S. Disturbed calcium-phosphorus metabolisml arterial calcificatios. In: Berbary A., Mancia G., eds. Cardiorenal syndrome. Springer; 2010. 269.Ritz E. Management of pts with chronic kidney disease and cardiovascular disease. In: Berbary A., Mancia G., eds. Cardiorenal syndrome. Springer; 2010. 359.Mallamaci F., Leonardi D., Borrajo M. Role of novel biomarkers in chronic kidney disease: urotensin II. In Berbary A., Mancia G., eds. Cardiorenal syndrome. Springer; 2010. 299.Кутырина И. М., Савельева С. А., Крячкова А. А. и др. Вклад ожирения в поражение почек у больных сахарным диабетом 2-го типа. Тер. арх. 2010; 6: 21-25.Flynn C., Bakris G. Interaction between adiponectin and aldosterone. Cardiorenal Med. 2011; 1: 96-101.Liang K., Williams A., Greene E. et al. Acute decompensated heart failure and cardiorenal syndrome. Crit. Care Med. 2008; 36 (Suppl. 1): 75.Singh D. Insufficient natriuretic response to furosemide predicts worsening renal function in acute decompensated heart failure independent of baseline renal function. J. Am. Coll. Cardiol. 2011; 57 (17): 1017.Sackner-Bernstein J., Scopicki H., Aaronson K. Risk of worsening renal function with nesiritide in pts with heart failure. Circulation 2005; 111: 1487.Cotter G., Dittrich H., Weatherley B. et al. The PROTECT study: a study of the adenosine A1 receptor antagonist rolofylline in pts with acute heart failure and renal impairment. J. Card. Fail. 2008; 14: 631.Konstam M., Gheorgiade M., Burnett J. et al. Efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) investigators. J. A. M. A. 2007; 297: 1319.Guyton A. C., Hall J. E. Textbook of medical physiology. New York: Saunders; 2000.Ronco C., Haapio M., House A. A. et al. Cardiorenal syndrome. J. Am. Coll. Cardiol. 2008; 52: 1527-1539.Ronco C., McCullough P., Anker S. D. et al. Acute Dialysis Quality Initiative (ADQI) consensus group: Cardiorenal syndromes: report from the consensus conference of the acute dialysis and quality initiative. Eur. Heart. J. 2010; 31: 703-711.Ronco C. The cardiorenal syndrome: Basis and common ground for a multidisciplinary patient-oriented therapy. Cardiorenal. Med. 2011; 1: 3-4.